Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029
The gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2% during the forecast period.
Factors such as advancements in gene editing technologies, and the expanding range of gene editing applications are driving the growth of the gene editing market. However, the market faces several challenges due to off-target effects of gene editing, along with difficulties in scalability and manufacturing, pose significant hurdles.
“The product segment accounted for the largest share by offerings segment in the gene editing market in 2023”
By offerings, the gene editing market is segmented into products and services. The products segment held the largest share in 2023. The demand for products in gene editing process including experimentation and research for cell line development and drug development & discovery make them an indispensable part of the gene market. Gene editing products as reagents & consumables and Software & systems like gene editing kits, gene editing reagents and gene editing libraries are utilized by pharmaceutican & biotechnology companies and academic & research institutes in various gene editing workflow. Services held the second highest share of the gene editing market in 2023.
“The CRISPR technology held the highest market share of the gene editing products market by technology in 2023”
By Technology, the gene editing products market is segmented into CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies which include piggybac and prime editing among others. The CRISPR segment held the highest share of the gene editing products by technology market in 2023 driven by advancements in CRISPR technology leading to large scale adoption of this technology in gene editing. Gene editing products are used in a large range of CRISPR applications including reagents like Cas-9, vectors, libraries for screening and target identification and CRISPR based gene editing kits. Still, TALEN segment held the second largest share of the market in 2023.
“The Asia Pacific region is growing at the highest CAGR in the gene editing market from 2024 to 2029.”
The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a significant focus on R&D activities, funding by government and private players in gene editing research, and rising adoption of gene editing technologies in drug discovery & development. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of gene editing technologies in healthcare management and treatment driving the market growth. However, North America held the largest share of gene editing market in 2023.
The primary interviews conducted for this report can be categorized as follows:
This research report categorizes the gene editing market by offerings (products and services), products by type (reagnets & consumables, and software & systems), reagents & consumables by Technique (knock-out, knock-in, gene silencing, and other techniques), products by technology (CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies), products by application (cell line engineering, genome editing/genetic engineering, drug discovery & development, and other applications), products by end user (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and other end users), services by type (cell line engineering, gRNA synthesis & vector construction, library construction & screening, and other types), services by application (cell line development & engineering, genome editing/genetic engineering, drug discovery & development, and other applications), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the genomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the gene editing market. Competitive analysis of top players and upcoming startups in the gene editing market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene editing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Increasing demand for personalized medicine, Favorable government funding investments for gene editing projects, Expanding applications of gene editing), restraints (Off-Target Effects and Safety Concerns), opportunities (Technological advancements in Prime editing and bridge RNA, Rising burden of congenital disorders), and challenges (Issues with scalability of gene editing workflows. High equipment and facility costs) influencing the growth of the market.
Factors such as advancements in gene editing technologies, and the expanding range of gene editing applications are driving the growth of the gene editing market. However, the market faces several challenges due to off-target effects of gene editing, along with difficulties in scalability and manufacturing, pose significant hurdles.
“The product segment accounted for the largest share by offerings segment in the gene editing market in 2023”
By offerings, the gene editing market is segmented into products and services. The products segment held the largest share in 2023. The demand for products in gene editing process including experimentation and research for cell line development and drug development & discovery make them an indispensable part of the gene market. Gene editing products as reagents & consumables and Software & systems like gene editing kits, gene editing reagents and gene editing libraries are utilized by pharmaceutican & biotechnology companies and academic & research institutes in various gene editing workflow. Services held the second highest share of the gene editing market in 2023.
“The CRISPR technology held the highest market share of the gene editing products market by technology in 2023”
By Technology, the gene editing products market is segmented into CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies which include piggybac and prime editing among others. The CRISPR segment held the highest share of the gene editing products by technology market in 2023 driven by advancements in CRISPR technology leading to large scale adoption of this technology in gene editing. Gene editing products are used in a large range of CRISPR applications including reagents like Cas-9, vectors, libraries for screening and target identification and CRISPR based gene editing kits. Still, TALEN segment held the second largest share of the market in 2023.
“The Asia Pacific region is growing at the highest CAGR in the gene editing market from 2024 to 2029.”
The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a significant focus on R&D activities, funding by government and private players in gene editing research, and rising adoption of gene editing technologies in drug discovery & development. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of gene editing technologies in healthcare management and treatment driving the market growth. However, North America held the largest share of gene editing market in 2023.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.
- Thermo fisher scientific Inc. (US)
- Merck KGaA (Germany)
- GenScript (US)
- Agilent Technologies, Inc. (US)
- Revvity (US)
- Lonza (US)
- Tecan Trading AG (Switzerland)
- Sangamo therapeutics (US)
- Precision BioSciences (US)
- Cellectis S.A. (France)
- Regeneron Pharmaceuticals Inc. (US)
- AMSBIO (UK)
- Creative Biogene (US)
- Synthego (US)
- Takara Bio Inc. (Japan)
- Bio-Techne (US)
- Caribou Biosciences, Inc. (US)
- Bioneer corporation (South Korea)
- REPROCELL Inc. (Japan)
This research report categorizes the gene editing market by offerings (products and services), products by type (reagnets & consumables, and software & systems), reagents & consumables by Technique (knock-out, knock-in, gene silencing, and other techniques), products by technology (CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies), products by application (cell line engineering, genome editing/genetic engineering, drug discovery & development, and other applications), products by end user (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and other end users), services by type (cell line engineering, gRNA synthesis & vector construction, library construction & screening, and other types), services by application (cell line development & engineering, genome editing/genetic engineering, drug discovery & development, and other applications), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the genomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the gene editing market. Competitive analysis of top players and upcoming startups in the gene editing market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene editing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Increasing demand for personalized medicine, Favorable government funding investments for gene editing projects, Expanding applications of gene editing), restraints (Off-Target Effects and Safety Concerns), opportunities (Technological advancements in Prime editing and bridge RNA, Rising burden of congenital disorders), and challenges (Issues with scalability of gene editing workflows. High equipment and facility costs) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched product/services of the gene editing market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the gene editing market
- Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript (US), Agilent Technologies, Inc. (US), Revvity (US), Lonza (US), Tecan Trading AG (Switzerland), Sangamo therapeutics (US). Precision BioSciences (US), Cellectis S.A. (France), Regeneron Pharmaceuticals Inc. (US), AMSBIO (UK), Creative Biogene (US), Synthego (US), Takara Bio Inc. (Japan), Bio-Techne (US), Caribou Biosciences, Inc. (US) Bioneer corporation (South Korea), and REPROCELL Inc. (Japan).
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 MARKET ESTIMATION
2.2.1.1 Insights of primary experts
2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GENE EDITING MARKET OVERVIEW
4.2 NORTH AMERICA: GENE EDITING MARKET, BY TYPE AND COUNTRY (2023)
4.3 GENE EDITING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing demand for personalized medicine
5.2.1.2 Favorable government funding investments for gene editing projects
5.2.1.3 Expanding applications of gene editing
5.2.2 RESTRAINTS
5.2.2.1 Off-target effects and safety concerns
5.2.3 OPPORTUNITIES
5.2.3.1 Rising technological advancements in prime editing and bridge RNA
5.2.3.2 Increasing burden of congenital disorders
5.2.4 CHALLENGES
5.2.4.1 Issues associated with scalability of gene editing workflows
5.2.4.2 High equipment & manufacturing costs
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY CONSUMABLE (2023)
5.4.2 AVERAGE COST RANGE OF GENE EDITING KITS & REAGENTS, 2021?2023
5.4.3 AVERAGE SELLING PRICE TREND OF SERVICES, BY TYPE
5.4.4 AVERAGE SELLING PRICE, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 IMPACT OF GENERATIVE AI ON GENE EDITING MARKET
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Next-generation sequencing
5.9.1.2 Electroporation
5.9.1.3 Microinjection
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Synthetic biology
5.9.2.2 Data analysis
5.9.2.3 High-throughput screening
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Single-cell analysis
5.9.3.2 Optogenetics
5.9.3.3 Gene delivery systems
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2024?2025
5.12 REGULATORY ANALYSIS
5.12.1 REGULATORY LANDSCAPE
5.12.1.1 North America
5.12.1.1.1 US
5.12.1.1.2 Canada
5.12.1.2 Europe
5.12.1.2.1 UK
5.12.1.3 Asia Pacific
5.12.1.3.1 China
5.12.1.3.2 Japan
5.12.1.3.3 South Korea
5.12.1.3.4 Australia
5.12.1.3.5 Rest of Asia Pacific
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA
5.15 CASE STUDY ANALYSIS
5.15.1 ENHANCED GENE KNOCK-IN EFFICIENCY USING HYBRID SSDNA HDR TEMPLATES IN PRIMARY HUMAN T-CELLS
5.15.2 GENE EDITING EFFICIENCY IN CANCER CELL LINES AND T-CELLS USING TRUECUT CAS9 PROTEIN V2 AND TRUEGUIDE SGRNA
5.15.3 DEVELOPMENT & SPECIFICITY OPTIMIZATION OF PUREDIT CRISPR CAS9 RNP SYSTEM
5.15.4 EVALUATION OF SUREGUIDE CAS9 PROGRAMMABLE NUCLEASE KIT FOR EFFICIENT IN VITRO GENE EDITING
5.15.5 GENE EDITING FOR SICKLE-CELL DISEASE USING ZINC FINGER NUCLEASE-MODIFIED HEMATOPOIETIC STEM CELLS
5.16 INVESTMENT & FUNDING SCENARIO
5.16.1 KEY INVESTMENTS & FUNDING ACTIVITIES, 2021?2024
5.17 TRADE DATA ANALYSIS
5.17.1 IMPORT DATA, 2019?2023
5.17.2 EXPORT DATA, 2019?2023
6 GENE EDITING MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 EXPANDING APPLICATIONS OF GENE MODIFICATION TECHNIQUES TO
DRIVE MARKET
6.3 SERVICES
6.3.1 HIGH UPTAKE BY PHARMA COMPANIES FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
7 GENE EDITING PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 REAGENTS & CONSUMABLES
7.2.1 GENE EDITING KITS
7.2.1.1 Increasing demand for mutation & screening kits in
clinical settings to propel market
7.2.2 GENE EDITING LIBRARIES
7.2.2.1 Genetic screening for cancer research to fuel uptake
7.2.3 GENE EDITING REAGENTS
7.2.3.1 Ability to create animal models to support market growth
7.3 SOFTWARE & SYSTEMS
7.3.1 INTEGRATION OF CLOUD-BASED PLATFORMS FOR NGS TO DRIVE MARKET
8 GENE EDITING REAGENTS & CONSUMABLES MARKET, BY TECHNIQUE
8.1 INTRODUCTION
8.2 KNOCK-OUT
8.2.1 MODIFICATION OF CRISPR-CAS9 AND TALENS TO PROPEL MARKET
8.3 KNOCK-IN
8.3.1 UTILIZATION OF DONOR DNA TEMPLATES AND HDR PATHWAYS TO
DRIVE MARKET
8.4 GENE SILENCING
8.4.1 ADVANCEMENTS IN RNAI TECHNOLOGY AND ANTISENSE THERAPY TO SUPPORT MARKET GROWTH
8.5 OTHER TECHNIQUES
9 GENE EDITING PRODUCTS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 CRISPR
9.2.1 ADVANCEMENTS IN CAS9 PROTEINS TO FUEL UPTAKE
9.3 TALENS
9.3.1 INCREASING DEMAND FOR THERAPEUTIC DEVELOPMENT TO DRIVE MARKET
9.4 ZFN
9.4.1 PROVISION OF CUSTOMIZED DESIGN AND TARGETED EDITS TO
BOOST DEMAND
9.5 BASE EDITING
9.5.1 GROWING APPLICATIONS IN FUNCTIONAL GENOMICS TO FUEL MARKET
9.6 ANTISENSE
9.6.1 INNOVATIONS IN OLIGONUCLEOTIDE THERAPIES TO SUPPORT MARKET GROWTH
9.7 RNAI
9.7.1 WIDE APPLICATIONS IN DRUG DISCOVERY TO FUEL UPTAKE
9.8 OTHER TECHNOLOGIES
10 GENE EDITING PRODUCTS MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 CELL LINE ENGINEERING
10.2.1 ABILITY TO PROVIDE PRECISE GENE MODIFICATIONS FOR VALIDATION
TO DRIVE MARKET
10.3 GENOME EDITING
10.3.1 GROWING APPLICATIONS IN BIOTECHNOLOGY TO BOOST DEMAND
10.4 DRUG DISCOVERY & DEVELOPMENT
10.4.1 UPTAKE OF CRISPR-BASED SYSTEMS FOR DISEASE PROFILING TO
DRIVE MARKET
10.5 OTHER APPLICATIONS
11 GENE EDITING PRODUCTS MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL
PIPELINE TO PROPEL MARKET
11.3 ACADEMIC & RESEARCH INSTITUTES
11.3.1 FAVORABLE FUNDING FOR GENOMIC PROJECTS TO DRIVE MARKET
11.4 CROS & CDMOS
11.4.1 PROVISION OF SPECIALIZED EXPERTISE FOR CLINICAL TRIALS TO
DRIVE MARKET
11.5 OTHER END USERS
12 GENE EDITING SERVICES MARKET, BY TYPE
12.1 INTRODUCTION
12.2 CELL LINE DEVELOPMENT & ENGINEERING
12.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
12.3 GRNA SYNTHESIS & VECTOR CONSTRUCTION
12.3.1 ADVANCEMENTS IN GENE EDITING TECHNOLOGIES AND DEMAND FOR PRECISE TARGETING TO DRIVE MARKET
12.4 LIBRARY CONSTRUCTION & SCREENING
12.4.1 INCREASING FOCUS ON HIGH-THROUGHPUT SCREENING TO PROPEL MARKET
12.5 OTHER SERVICES
12.5.1 OTHER SERVICES INCLUDE OFF-TARGET ANALYSIS AND MUTAGENESIS SERVICES.
13 GENE EDITING SERVICES MARKET, BY APPLICATION
13.1 INTRODUCTION
13.2 CELL LINE ENGINEERING
13.2.1 HIGH UPTAKE IN R&D FOR THERAPEUTIC BIOPRODUCTION TO DRIVE MARKET
13.3 GENOME EDITING
13.3.1 GROWING FOCUS ON SYNTHETIC GENOMICS TO BOOST DEMAND
13.4 DRUG DISCOVERY & DEVELOPMENT
13.4.1 GROWING DEMAND FOR PHARMACEUTICAL DEVELOPMENT TO FUEL UPTAKE
13.5 OTHER APPLICATIONS
14 GENE EDITING SERVICES MARKET, BY END USER
14.1 INTRODUCTION
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.2.1 GROWING DEMAND FOR ADVANCED MODALITIES TO DRIVE MARKET
14.3 ACADEMIC & RESEARCH INSTITUTES
14.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
14.4 OTHER END USERS
15 GENE EDITING MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 Growing investments by government authorities and private players to drive market
15.2.3 CANADA
15.2.3.1 Rise in research & development initiatives for genomics and biotechnology to augment growth
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 Growing focus on promoting innovations in biotechnology sector to boost market
15.3.3 FRANCE
15.3.3.1 Ongoing clinical trials and advanced genomic research to
promote growth
15.3.4 UK
15.3.4.1 Growing focus on developing cell and gene therapy infrastructure to fuel market
15.3.5 ITALY
15.3.5.1 Increasing availability of research funds to expedite growth
15.3.6 SPAIN
15.3.6.1 Booming biotechnology sector to contribute to market growth
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 CHINA
15.4.2.1 Increasing affordability of sequencing platforms and procedures to favor growth
15.4.3 JAPAN
15.4.3.1 Growing focus on cancer research to fuel market
15.4.4 INDIA
15.4.4.1 Increased awareness about therapeutic benefits of genome engineering to encourage growth
15.4.5 SOUTH KOREA
15.4.5.1 Rising inclination toward in vivo gene editing to stimulate growth
15.4.6 AUSTRALIA
15.4.6.1 Favorable regulatory landscape to sustain growth
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market
15.5.3 REST OF LATIN AMERICA
15.6 MIDDLE EAST
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
15.6.2 GCC COUNTRIES
15.6.2.1 Kingdom of Saudi Arabia
15.6.2.1.1 Increasing establishment of biotech startups to
support market growth
15.6.2.2 United Arab Emirates (UAE)
15.6.2.2.1 Growing collaborations for genome sequencing to
drive market
15.6.2.3 Other GCC Countries
15.6.3 REST OF MIDDLE EAST
15.7 AFRICA
15.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
15.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021?2024
16.3 REVENUE ANALYSIS, 2019?2023
16.4 MARKET SHARE ANALYSIS, 2023
16.4.1 RANKING OF KEY MARKET PLAYERS
16.5 COMPANY VALUATION AND FINANCIAL METRICS
16.5.1 COMPANY VALUATION
16.5.2 FINANCIAL METRICS
16.6 BRAND/PRODUCT COMPARISON
16.6.1 THERMO FISHER SCIENTIFIC INC. (US)
16.6.2 MERCK KGAA (GERMANY)
16.6.3 GENSCRIPT (US)
16.6.4 AGILENT TECHNOLOGIES, INC. (US)
16.6.5 REVVITY, INC. (US)
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
16.7.1 STARS
16.7.2 EMERGING LEADERS
16.7.3 PERVASIVE PLAYERS
16.7.4 PARTICIPANTS
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
16.7.5.1 Company footprint
16.7.5.2 Product footprint
16.7.5.3 Service footprint
16.7.5.4 Technology footprint
16.7.5.5 Region footprint
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
16.8.1 PROGRESSIVE COMPANIES
16.8.2 RESPONSIVE COMPANIES
16.8.3 DYNAMIC COMPANIES
16.8.4 STARTING BLOCKS
16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
16.8.5.1 Detailed list of key startups/SMEs
16.8.5.2 Competitive benchmarking of key startups/SMEs
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
16.9.2 DEALS
16.9.3 EXPANSIONS
17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 THERMO FISHER SCIENTIFIC INC.
17.1.1.1 Business overview
17.1.1.2 Products/Services offered
17.1.1.3 Recent developments
17.1.1.3.1 Product/Service launches & approvals
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses & competitive threats
17.1.2 MERCK KGAA
17.1.2.1 Business overview
17.1.2.2 Products/Services offered
17.1.2.3 Recent developments
17.1.2.3.1 Deals
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses & competitive threats
17.1.3 GENSCRIPT
17.1.3.1 Business overview
17.1.3.2 Products/Services offered
17.1.3.3 Recent developments
17.1.3.3.1 Product/Service launches & approvals
17.1.3.3.2 Deals
17.1.3.3.3 Expansions
17.1.3.4 MnM view
17.1.3.4.1 Key strengths
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses and competitive threats
17.1.4 AGILENT TECHNOLOGIES, INC.
17.1.4.1 Business overview
17.1.4.2 Products/Services offered
17.1.4.3 Recent developments
17.1.4.3.1 Deals
17.1.4.3.2 Expansions
17.1.4.4 MnM view
17.1.4.4.1 Key strengths
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses & competitive threats
17.1.5 REVVITY, INC.
17.1.5.1 Business overview
17.1.5.2 Products/Services offered
17.1.5.3 Recent developments
17.1.5.3.1 Product/Service launches
17.1.5.3.2 Deals
17.1.5.4 MnM view
17.1.5.4.1 Key strengths
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weakness & competitive threats
17.1.6 LONZA
17.1.6.1 Business overview
17.1.6.2 Products/Services offered
17.1.6.3 Recent developments
17.1.6.3.1 Product/Service launches
17.1.7 TECAN TRADING AG
17.1.7.1 Business overview
17.1.7.2 Products/Services offered
17.1.7.3 Recent developments
17.1.7.3.1 Deals
17.1.8 SANGAMO THERAPEUTICS
17.1.8.1 Business overview
17.1.8.2 Products/Services offered
17.1.8.3 Recent developments
17.1.8.3.1 Deals
17.1.9 PRECISION BIOSCIENCES
17.1.9.1 Business overview
17.1.9.2 Products/Services offered
17.1.9.3 Recent developments
17.1.9.3.1 Deals
17.1.10 CELLECTIS S.A.
17.1.10.1 Business overview
17.1.10.2 Products/Services offered
17.1.10.3 Recent developments
17.1.10.3.1 Deals
17.1.11 REGENERON PHARMACEUTICALS, INC.
17.1.11.1 Business overview
17.1.11.2 Products/Services offered
17.1.11.3 Recent developments
17.1.11.3.1 Deals
17.1.12 AMSBIO
17.1.12.1 Business overview
17.1.12.2 Products/Services offered
17.1.13 CREATIVE BIOGENE
17.1.13.1 Business overview
17.1.13.2 Products/Services offered
17.1.14 SYNTHEGO
17.1.14.1 Business overview
17.1.14.2 Products/Services offered
17.1.14.3 Recent developments
17.1.14.3.1 Product/Service launches
17.1.14.3.2 Deals
17.1.14.3.3 Expansions
17.1.15 TAKARA BIO INC.
17.1.15.1 Business overview
17.1.15.2 Products/Services offered
17.1.15.3 Recent developments
17.1.15.3.1 Deals
17.1.15.3.2 Expansions
17.1.16 BIO-TECHNE
17.1.16.1 Business overview
17.1.16.2 Products/Services offered
17.1.16.3 Recent developments
17.1.16.3.1 Deals
17.1.16.3.2 Expansions
17.1.17 CARIBOU BIOSCIENCES, INC.
17.1.17.1 Business overview
17.1.17.2 Products/Services offered
17.1.17.3 Recent developments
17.1.17.3.1 Deals
17.1.18 BIONEER CORPORATION
17.1.18.1 Business overview
17.1.18.2 Products/Services offered
17.1.19 REPROCELL INC.
17.1.19.1 Business overview
17.1.19.2 Products/Services offered
17.2 OTHER PLAYERS
17.2.1 ALSTEM INC.
17.2.2 NEW ENGLAND BIOLABS
17.2.3 INSCRIPTA, INC.
17.2.4 BIOCAT GMBH.
17.2.5 INTEGRATED DNA TECHNOLOGIES, INC.
17.2.6 COBO TECHNOLOGIES APS
17.2.7 GENECOPOEIA, INC.
17.2.8 HERA BIOLABS
17.2.9 STEMCELL TECHNOLOGIES.
17.2.10 AXOL BIOSCIENCE LTD.
17.2.11 CELLECTA, INC.
17.2.12 APPLIED STEMCELL
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 MARKET ESTIMATION
2.2.1.1 Insights of primary experts
2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 GENE EDITING MARKET OVERVIEW
4.2 NORTH AMERICA: GENE EDITING MARKET, BY TYPE AND COUNTRY (2023)
4.3 GENE EDITING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing demand for personalized medicine
5.2.1.2 Favorable government funding investments for gene editing projects
5.2.1.3 Expanding applications of gene editing
5.2.2 RESTRAINTS
5.2.2.1 Off-target effects and safety concerns
5.2.3 OPPORTUNITIES
5.2.3.1 Rising technological advancements in prime editing and bridge RNA
5.2.3.2 Increasing burden of congenital disorders
5.2.4 CHALLENGES
5.2.4.1 Issues associated with scalability of gene editing workflows
5.2.4.2 High equipment & manufacturing costs
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY CONSUMABLE (2023)
5.4.2 AVERAGE COST RANGE OF GENE EDITING KITS & REAGENTS, 2021?2023
5.4.3 AVERAGE SELLING PRICE TREND OF SERVICES, BY TYPE
5.4.4 AVERAGE SELLING PRICE, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 IMPACT OF GENERATIVE AI ON GENE EDITING MARKET
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Next-generation sequencing
5.9.1.2 Electroporation
5.9.1.3 Microinjection
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Synthetic biology
5.9.2.2 Data analysis
5.9.2.3 High-throughput screening
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Single-cell analysis
5.9.3.2 Optogenetics
5.9.3.3 Gene delivery systems
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2024?2025
5.12 REGULATORY ANALYSIS
5.12.1 REGULATORY LANDSCAPE
5.12.1.1 North America
5.12.1.1.1 US
5.12.1.1.2 Canada
5.12.1.2 Europe
5.12.1.2.1 UK
5.12.1.3 Asia Pacific
5.12.1.3.1 China
5.12.1.3.2 Japan
5.12.1.3.3 South Korea
5.12.1.3.4 Australia
5.12.1.3.5 Rest of Asia Pacific
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF BUYERS
5.13.4 BARGAINING POWER OF SUPPLIERS
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA
5.15 CASE STUDY ANALYSIS
5.15.1 ENHANCED GENE KNOCK-IN EFFICIENCY USING HYBRID SSDNA HDR TEMPLATES IN PRIMARY HUMAN T-CELLS
5.15.2 GENE EDITING EFFICIENCY IN CANCER CELL LINES AND T-CELLS USING TRUECUT CAS9 PROTEIN V2 AND TRUEGUIDE SGRNA
5.15.3 DEVELOPMENT & SPECIFICITY OPTIMIZATION OF PUREDIT CRISPR CAS9 RNP SYSTEM
5.15.4 EVALUATION OF SUREGUIDE CAS9 PROGRAMMABLE NUCLEASE KIT FOR EFFICIENT IN VITRO GENE EDITING
5.15.5 GENE EDITING FOR SICKLE-CELL DISEASE USING ZINC FINGER NUCLEASE-MODIFIED HEMATOPOIETIC STEM CELLS
5.16 INVESTMENT & FUNDING SCENARIO
5.16.1 KEY INVESTMENTS & FUNDING ACTIVITIES, 2021?2024
5.17 TRADE DATA ANALYSIS
5.17.1 IMPORT DATA, 2019?2023
5.17.2 EXPORT DATA, 2019?2023
6 GENE EDITING MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 EXPANDING APPLICATIONS OF GENE MODIFICATION TECHNIQUES TO
DRIVE MARKET
6.3 SERVICES
6.3.1 HIGH UPTAKE BY PHARMA COMPANIES FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
7 GENE EDITING PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 REAGENTS & CONSUMABLES
7.2.1 GENE EDITING KITS
7.2.1.1 Increasing demand for mutation & screening kits in
clinical settings to propel market
7.2.2 GENE EDITING LIBRARIES
7.2.2.1 Genetic screening for cancer research to fuel uptake
7.2.3 GENE EDITING REAGENTS
7.2.3.1 Ability to create animal models to support market growth
7.3 SOFTWARE & SYSTEMS
7.3.1 INTEGRATION OF CLOUD-BASED PLATFORMS FOR NGS TO DRIVE MARKET
8 GENE EDITING REAGENTS & CONSUMABLES MARKET, BY TECHNIQUE
8.1 INTRODUCTION
8.2 KNOCK-OUT
8.2.1 MODIFICATION OF CRISPR-CAS9 AND TALENS TO PROPEL MARKET
8.3 KNOCK-IN
8.3.1 UTILIZATION OF DONOR DNA TEMPLATES AND HDR PATHWAYS TO
DRIVE MARKET
8.4 GENE SILENCING
8.4.1 ADVANCEMENTS IN RNAI TECHNOLOGY AND ANTISENSE THERAPY TO SUPPORT MARKET GROWTH
8.5 OTHER TECHNIQUES
9 GENE EDITING PRODUCTS MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 CRISPR
9.2.1 ADVANCEMENTS IN CAS9 PROTEINS TO FUEL UPTAKE
9.3 TALENS
9.3.1 INCREASING DEMAND FOR THERAPEUTIC DEVELOPMENT TO DRIVE MARKET
9.4 ZFN
9.4.1 PROVISION OF CUSTOMIZED DESIGN AND TARGETED EDITS TO
BOOST DEMAND
9.5 BASE EDITING
9.5.1 GROWING APPLICATIONS IN FUNCTIONAL GENOMICS TO FUEL MARKET
9.6 ANTISENSE
9.6.1 INNOVATIONS IN OLIGONUCLEOTIDE THERAPIES TO SUPPORT MARKET GROWTH
9.7 RNAI
9.7.1 WIDE APPLICATIONS IN DRUG DISCOVERY TO FUEL UPTAKE
9.8 OTHER TECHNOLOGIES
10 GENE EDITING PRODUCTS MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 CELL LINE ENGINEERING
10.2.1 ABILITY TO PROVIDE PRECISE GENE MODIFICATIONS FOR VALIDATION
TO DRIVE MARKET
10.3 GENOME EDITING
10.3.1 GROWING APPLICATIONS IN BIOTECHNOLOGY TO BOOST DEMAND
10.4 DRUG DISCOVERY & DEVELOPMENT
10.4.1 UPTAKE OF CRISPR-BASED SYSTEMS FOR DISEASE PROFILING TO
DRIVE MARKET
10.5 OTHER APPLICATIONS
11 GENE EDITING PRODUCTS MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL
PIPELINE TO PROPEL MARKET
11.3 ACADEMIC & RESEARCH INSTITUTES
11.3.1 FAVORABLE FUNDING FOR GENOMIC PROJECTS TO DRIVE MARKET
11.4 CROS & CDMOS
11.4.1 PROVISION OF SPECIALIZED EXPERTISE FOR CLINICAL TRIALS TO
DRIVE MARKET
11.5 OTHER END USERS
12 GENE EDITING SERVICES MARKET, BY TYPE
12.1 INTRODUCTION
12.2 CELL LINE DEVELOPMENT & ENGINEERING
12.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
12.3 GRNA SYNTHESIS & VECTOR CONSTRUCTION
12.3.1 ADVANCEMENTS IN GENE EDITING TECHNOLOGIES AND DEMAND FOR PRECISE TARGETING TO DRIVE MARKET
12.4 LIBRARY CONSTRUCTION & SCREENING
12.4.1 INCREASING FOCUS ON HIGH-THROUGHPUT SCREENING TO PROPEL MARKET
12.5 OTHER SERVICES
12.5.1 OTHER SERVICES INCLUDE OFF-TARGET ANALYSIS AND MUTAGENESIS SERVICES.
13 GENE EDITING SERVICES MARKET, BY APPLICATION
13.1 INTRODUCTION
13.2 CELL LINE ENGINEERING
13.2.1 HIGH UPTAKE IN R&D FOR THERAPEUTIC BIOPRODUCTION TO DRIVE MARKET
13.3 GENOME EDITING
13.3.1 GROWING FOCUS ON SYNTHETIC GENOMICS TO BOOST DEMAND
13.4 DRUG DISCOVERY & DEVELOPMENT
13.4.1 GROWING DEMAND FOR PHARMACEUTICAL DEVELOPMENT TO FUEL UPTAKE
13.5 OTHER APPLICATIONS
14 GENE EDITING SERVICES MARKET, BY END USER
14.1 INTRODUCTION
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.2.1 GROWING DEMAND FOR ADVANCED MODALITIES TO DRIVE MARKET
14.3 ACADEMIC & RESEARCH INSTITUTES
14.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
14.4 OTHER END USERS
15 GENE EDITING MARKET, BY REGION
15.1 INTRODUCTION
15.2 NORTH AMERICA
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
15.2.2 US
15.2.2.1 Growing investments by government authorities and private players to drive market
15.2.3 CANADA
15.2.3.1 Rise in research & development initiatives for genomics and biotechnology to augment growth
15.3 EUROPE
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
15.3.2 GERMANY
15.3.2.1 Growing focus on promoting innovations in biotechnology sector to boost market
15.3.3 FRANCE
15.3.3.1 Ongoing clinical trials and advanced genomic research to
promote growth
15.3.4 UK
15.3.4.1 Growing focus on developing cell and gene therapy infrastructure to fuel market
15.3.5 ITALY
15.3.5.1 Increasing availability of research funds to expedite growth
15.3.6 SPAIN
15.3.6.1 Booming biotechnology sector to contribute to market growth
15.3.7 REST OF EUROPE
15.4 ASIA PACIFIC
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
15.4.2 CHINA
15.4.2.1 Increasing affordability of sequencing platforms and procedures to favor growth
15.4.3 JAPAN
15.4.3.1 Growing focus on cancer research to fuel market
15.4.4 INDIA
15.4.4.1 Increased awareness about therapeutic benefits of genome engineering to encourage growth
15.4.5 SOUTH KOREA
15.4.5.1 Rising inclination toward in vivo gene editing to stimulate growth
15.4.6 AUSTRALIA
15.4.6.1 Favorable regulatory landscape to sustain growth
15.4.7 REST OF ASIA PACIFIC
15.5 LATIN AMERICA
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
15.5.2 BRAZIL
15.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market
15.5.3 REST OF LATIN AMERICA
15.6 MIDDLE EAST
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
15.6.2 GCC COUNTRIES
15.6.2.1 Kingdom of Saudi Arabia
15.6.2.1.1 Increasing establishment of biotech startups to
support market growth
15.6.2.2 United Arab Emirates (UAE)
15.6.2.2.1 Growing collaborations for genome sequencing to
drive market
15.6.2.3 Other GCC Countries
15.6.3 REST OF MIDDLE EAST
15.7 AFRICA
15.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
15.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
16 COMPETITIVE LANDSCAPE
16.1 INTRODUCTION
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021?2024
16.3 REVENUE ANALYSIS, 2019?2023
16.4 MARKET SHARE ANALYSIS, 2023
16.4.1 RANKING OF KEY MARKET PLAYERS
16.5 COMPANY VALUATION AND FINANCIAL METRICS
16.5.1 COMPANY VALUATION
16.5.2 FINANCIAL METRICS
16.6 BRAND/PRODUCT COMPARISON
16.6.1 THERMO FISHER SCIENTIFIC INC. (US)
16.6.2 MERCK KGAA (GERMANY)
16.6.3 GENSCRIPT (US)
16.6.4 AGILENT TECHNOLOGIES, INC. (US)
16.6.5 REVVITY, INC. (US)
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
16.7.1 STARS
16.7.2 EMERGING LEADERS
16.7.3 PERVASIVE PLAYERS
16.7.4 PARTICIPANTS
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
16.7.5.1 Company footprint
16.7.5.2 Product footprint
16.7.5.3 Service footprint
16.7.5.4 Technology footprint
16.7.5.5 Region footprint
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
16.8.1 PROGRESSIVE COMPANIES
16.8.2 RESPONSIVE COMPANIES
16.8.3 DYNAMIC COMPANIES
16.8.4 STARTING BLOCKS
16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
16.8.5.1 Detailed list of key startups/SMEs
16.8.5.2 Competitive benchmarking of key startups/SMEs
16.9 COMPETITIVE SCENARIO
16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
16.9.2 DEALS
16.9.3 EXPANSIONS
17 COMPANY PROFILES
17.1 KEY PLAYERS
17.1.1 THERMO FISHER SCIENTIFIC INC.
17.1.1.1 Business overview
17.1.1.2 Products/Services offered
17.1.1.3 Recent developments
17.1.1.3.1 Product/Service launches & approvals
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 MnM view
17.1.1.4.1 Key strengths
17.1.1.4.2 Strategic choices
17.1.1.4.3 Weaknesses & competitive threats
17.1.2 MERCK KGAA
17.1.2.1 Business overview
17.1.2.2 Products/Services offered
17.1.2.3 Recent developments
17.1.2.3.1 Deals
17.1.2.4 MnM view
17.1.2.4.1 Key strengths
17.1.2.4.2 Strategic choices
17.1.2.4.3 Weaknesses & competitive threats
17.1.3 GENSCRIPT
17.1.3.1 Business overview
17.1.3.2 Products/Services offered
17.1.3.3 Recent developments
17.1.3.3.1 Product/Service launches & approvals
17.1.3.3.2 Deals
17.1.3.3.3 Expansions
17.1.3.4 MnM view
17.1.3.4.1 Key strengths
17.1.3.4.2 Strategic choices
17.1.3.4.3 Weaknesses and competitive threats
17.1.4 AGILENT TECHNOLOGIES, INC.
17.1.4.1 Business overview
17.1.4.2 Products/Services offered
17.1.4.3 Recent developments
17.1.4.3.1 Deals
17.1.4.3.2 Expansions
17.1.4.4 MnM view
17.1.4.4.1 Key strengths
17.1.4.4.2 Strategic choices
17.1.4.4.3 Weaknesses & competitive threats
17.1.5 REVVITY, INC.
17.1.5.1 Business overview
17.1.5.2 Products/Services offered
17.1.5.3 Recent developments
17.1.5.3.1 Product/Service launches
17.1.5.3.2 Deals
17.1.5.4 MnM view
17.1.5.4.1 Key strengths
17.1.5.4.2 Strategic choices
17.1.5.4.3 Weakness & competitive threats
17.1.6 LONZA
17.1.6.1 Business overview
17.1.6.2 Products/Services offered
17.1.6.3 Recent developments
17.1.6.3.1 Product/Service launches
17.1.7 TECAN TRADING AG
17.1.7.1 Business overview
17.1.7.2 Products/Services offered
17.1.7.3 Recent developments
17.1.7.3.1 Deals
17.1.8 SANGAMO THERAPEUTICS
17.1.8.1 Business overview
17.1.8.2 Products/Services offered
17.1.8.3 Recent developments
17.1.8.3.1 Deals
17.1.9 PRECISION BIOSCIENCES
17.1.9.1 Business overview
17.1.9.2 Products/Services offered
17.1.9.3 Recent developments
17.1.9.3.1 Deals
17.1.10 CELLECTIS S.A.
17.1.10.1 Business overview
17.1.10.2 Products/Services offered
17.1.10.3 Recent developments
17.1.10.3.1 Deals
17.1.11 REGENERON PHARMACEUTICALS, INC.
17.1.11.1 Business overview
17.1.11.2 Products/Services offered
17.1.11.3 Recent developments
17.1.11.3.1 Deals
17.1.12 AMSBIO
17.1.12.1 Business overview
17.1.12.2 Products/Services offered
17.1.13 CREATIVE BIOGENE
17.1.13.1 Business overview
17.1.13.2 Products/Services offered
17.1.14 SYNTHEGO
17.1.14.1 Business overview
17.1.14.2 Products/Services offered
17.1.14.3 Recent developments
17.1.14.3.1 Product/Service launches
17.1.14.3.2 Deals
17.1.14.3.3 Expansions
17.1.15 TAKARA BIO INC.
17.1.15.1 Business overview
17.1.15.2 Products/Services offered
17.1.15.3 Recent developments
17.1.15.3.1 Deals
17.1.15.3.2 Expansions
17.1.16 BIO-TECHNE
17.1.16.1 Business overview
17.1.16.2 Products/Services offered
17.1.16.3 Recent developments
17.1.16.3.1 Deals
17.1.16.3.2 Expansions
17.1.17 CARIBOU BIOSCIENCES, INC.
17.1.17.1 Business overview
17.1.17.2 Products/Services offered
17.1.17.3 Recent developments
17.1.17.3.1 Deals
17.1.18 BIONEER CORPORATION
17.1.18.1 Business overview
17.1.18.2 Products/Services offered
17.1.19 REPROCELL INC.
17.1.19.1 Business overview
17.1.19.2 Products/Services offered
17.2 OTHER PLAYERS
17.2.1 ALSTEM INC.
17.2.2 NEW ENGLAND BIOLABS
17.2.3 INSCRIPTA, INC.
17.2.4 BIOCAT GMBH.
17.2.5 INTEGRATED DNA TECHNOLOGIES, INC.
17.2.6 COBO TECHNOLOGIES APS
17.2.7 GENECOPOEIA, INC.
17.2.8 HERA BIOLABS
17.2.9 STEMCELL TECHNOLOGIES.
17.2.10 AXOL BIOSCIENCE LTD.
17.2.11 CELLECTA, INC.
17.2.12 APPLIED STEMCELL
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
